Answers are grounded in this paper and cite their sources.
This scoping review demonstrates substantial cost savings in switching from IVIg to SCIg, suggesting economic benefits for healthcare in Canada.
SCIg represents an important treatment option both for alleviating burden to the Canadian healthcare system and for patients. Substantial cost savings were estimated by switching from IVIg to SCIg. These findings provide evidence to support healthcare decision-making from an economic perspective.
No takes yet. Share an insight, caveat, or question.
Cheung et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: